EUCTR2012-001183-30-Outside-EU/EEA进行中（未招募）不适用
Double-blind trial investigating the safety and efficacy of the inhibitor anastrozole (arimidex) in delaying epiphyseal fusion and increasing height potential of adolescent males with growth hormone (GH) deficiency.
emours Children's Clinic0 个研究点目标入组 53 人开始时间: 2012年3月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 53
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Growth hormone deficient by formal testing with two provocative agents.
- •Treated with growth hormone for a minimum of 6 months prior to study entry.
- •Growth hormone doses must be maintained at 0.2-0.4mg/kg/wk while in protocol.
- •Stable organic pathology.
- •Presence of puberty (genital tanner stage > 11 (>4cc testicular volume).
- •Bone age (BA) > or = 11.5 years and < 15 years
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 53
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Participation in any other trial involving hormone therapy for at least 6 months prior.
- •Chronic illnesses requiring long term medication that impair growth. (stable patients with occasional asthma, patients on Ritalin or Adderall or patients on topical acne medication may be included).
- •Hereditary disease diagnosed clinically.
- •Moderate to severe scoliosis.
研究者
相似试验
已完成
3 期
Comparison of contrast media Dixopaque (Shahid Ghazi) and VisipaquePatients candidated for coronary angiography by contrast media.Ischemic Heart Diseases120-125IRCT201607254920N8Shahid Ghazi Pharmaceutical Company50
进行中（未招募）
不适用
A double-blind, randomised efficacy and safety study of taliglucerase alfa enzyme replacement therapy in children and adolescents with Gaucher disease (non-neuronopathic and chronic neuronopathic)Gaucher diseaseMedDRA version: 14.1Level: PTClassification code 10018048Term: Gaucher's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2007-000498-42-Outside-EU/EEAProtalix Biotherapeutics10
已完成
3 期
Double blind, randomized clinical trial on efficacy of combination of Glucantime and topical paromomycin for the treatment of cutaneous leishmaniasis caused by Leishmania tropicaProtozoal diseases.Cutaneous leishmaniasisIRCT138904241475N5The Eastern Mediterranean Regional Office (EMRO) of the World Health Organization (WHO)120
已完成
3 期
Clinical trial of efficacy of combination of topical liposomal Amphotericin B and meglumine antimoniate (Glucantime) the treatment of anthroponotic cutaneous leishmaniasis (ACL) caused by Leishmania tropica (Phase 3)Cutaneous leishmaniasis.Cutaneous leishmaniasisIRCT201504211475N7MoH, EMRO/WHO120
招募中
1 期
A randomized, double-blind trial of efficacy and mechanism of Shiwei Yiyuan granules for cancer-related fatigueITMCTR2100004481Xiyuan Hospital of China Academy of Chinese Medical Sciences